34 results
8-K
EX-10.1
TCRR
Tcr2 Therapeutics Inc
24 May 23
Entry into a Material Definitive Agreement
4:47pm
8-K
EX-10.2
TCRR
Tcr2 Therapeutics Inc
24 May 23
Entry into a Material Definitive Agreement
4:47pm
425
EX-10.3
TCRR
Tcr2 Therapeutics Inc
6 Mar 23
Business combination disclosure
6:41am
425
EX-10.1
TCRR
Tcr2 Therapeutics Inc
6 Mar 23
Business combination disclosure
6:41am
425
EX-10.2
TCRR
Tcr2 Therapeutics Inc
6 Mar 23
Business combination disclosure
6:41am
8-K
EX-10.1
at284
6 Mar 23
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
6:37am
8-K
EX-10.2
d165iplmkmb0 cm
6 Mar 23
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
6:37am
8-K
EX-10.3
f1uvw8z
6 Mar 23
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
6:37am
10-Q
EX-10.1
a9prdeivx
13 May 19
Quarterly report
4:21pm
S-1/A
EX-10.2
cdzoan 7mc
1 Feb 19
IPO registration (amended)
3:20pm
S-1/A
EX-10.4
s9om0pfwtsi50
1 Feb 19
IPO registration (amended)
3:20pm
S-1
EX-10.11
gayqe3r
28 Dec 18
IPO registration
1:48pm
S-1
EX-10.6
vo2fim
28 Dec 18
IPO registration
1:48pm
S-1
EX-10.3
1i33m0bx ou
28 Dec 18
IPO registration
1:48pm
S-1
EX-10.9
uy3uuu29bsvk061ar0
28 Dec 18
IPO registration
1:48pm
S-1
EX-10.13
kv22j
28 Dec 18
IPO registration
1:48pm
S-1
EX-10.1
4eashq67hite
28 Dec 18
IPO registration
1:48pm
S-1
EX-10.5
ogo8e20ri7 46n
28 Dec 18
IPO registration
1:48pm